Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305236 · ClinicalTrials.gov registry record · Phase 2
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
A Phase 2 study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04305236 is a Phase 2 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 1 participants.
The verdict
NCT04305236, a Phase 2 study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase 2 single-arm, open-label determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in subjects with Hormone receptor positive patients with localized non-metastatic breast cancer who develop local recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance.
Interventions
- DRUG Fulvestrant
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-07-23 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305236
The ClinicalTrials.gov registry entry for NCT04305236 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT04305236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04305236 about?
NCT04305236 is a clinical study titled "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer". This is a phase 2 single-arm, open-label determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in subjects with Hormone receptor positive patients with localized non-metastatic breast cancer who develop local recurrence while on adjuvant endocrine therapy with molecular evidence of endocr...
What is the current status of trial NCT04305236?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-07-23. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT04305236?
The interventions under investigation include: Fulvestrant (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04305236?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.